Adjuvant Therapy for completely resected Stage II Colon Cancer (Q24242231)

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

AXIS--a suitable case for treatment. UK Coordinating Committee on Cancer Research (UKCCCR) Colorectal Cancer Subcommittee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

An evaluation of the effectiveness and safety of razoxane when used as an adjunct to surgery in colo-rectal cancer. Report of a controlled randomised study of 603 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma: a randomized control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

An individual patient data meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Re: Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Adjuvant therapy of poor prognosis colon cancer with levamisole: results of an EORTC double-blind randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Adjuvant therapy of colorectal cancer. Why we still don't know

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Late mortality and levamisole adjuvant therapy in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Edrecolomab (Panorex) as adjuvant therapy for stage II colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Mature results of adjuvant colon cancer trials from the fluorouracil-only era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Update of clinical trials with edrecolomab: a monoclonal antibody therapy for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Effect of pre-operative short course famotidine on tumor infiltrating lymphocytes in colorectal cancer: a double blind, placebo controlled, prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Adjuvant therapy for colorectal cancer. The EORTC experience and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Peri-operative modulation of cellular immunity in patients with colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Ranitidine as adjuvant treatment in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tra

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

A trial of adjuvant therapy in colorectal cancer: the VICTOR trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Recent meta-analyses in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

A systematic overview of chemotherapy effects in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Randomized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Current issues in adjuvant treatment of stage II colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Should Dukes' B patients receive adjuvant therapy? A statistical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Disabling Encephalopathy During 5-Fluorouracil and Levamisole Adjuvant Therapy for Resected Colorectal Cancer: A Report of Two Cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Genomic instability and colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Intraperitoneal exfoliated cancer cells in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Adjuvant chemotherapy for stage II colorectal cancer: the time is right!

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Surgical adjuvant therapy for colorectal cancer: current approaches and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Is there a role for clinical prognostic factors in staging patients with colorectal cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Survival of patients with stage B2 colon carcinoma. The Gastrointestinal Tumor Study Group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Systematic review of microsatellite instability and colorectal cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I)

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Adjuvant chemotherapy with 5-fluorouracil, vincristine and CCNU for patients with Dukes' C colorectal cancer. The Swedish Gastrointestinal Tumour Adjuvant Therapy Group

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: five-year follow-up. Tokai HCFU Study Group--third study on colorectal cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Randomized trial of preoperative cimetidine in patients with colorectal carcinoma with quantitative assessment of tumor-associated lymphocytes

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Timing the collaborative analysis of three trials comparing 5-FU plus folinic acid (FUFA) to surgery alone in the management of resected colorectal cancer: a National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) perspective

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Active immunotherapy in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Interim analysis of a double-blind phase-III clinical trial of adjuvant levamisole versus control in resectable Dukes-C colon cancer: a study of the EORTC Gastrointestinal Tract Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Adjuvant intraperitoneal 5-fluorouracil and intravenous leucovorin after colorectal cancer surgery: a randomized phase II placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Prophylactic portal infusion chemotherapy as adjuvant therapy for the prevention of metachronous liver metastasis in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Clinical trials in colorectal cancer: experience of the Gastrointestinal Tumor Study Group and the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Intraportal chemotherapy in colorectal carcinoma as an adjuvant modality

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Cimetidine as an adjuvant treatment in colorectal cancer. A double-blind, randomized pilot study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Randomized trial of the efficacy of adjuvant chemotherapy for colon cancer with combination therapy incorporating the oral pyrimidine 1-hexylcarbamoyl-5-fluorouracil

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Adjuvant therapy with hepatic irradiation plus fluorouracil in colon carcinoma. The Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Clinically useful measures of effect in binary analyses of randomized trials

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Recent data with oxaliplatin-containing regimens in the adjuvant treatment of colorectal cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin 5-FU to levamisole 5-FU.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Lymph node evaluation in colorectal cancer patients: a population-based study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenter phase III trial

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Melbourne trial of adjuvant immunotherapy in operable large bowel cancer.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Adjuvant vaccination in colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Long-term survival following levamisole or placebo adjuvant treatment of colorectal cancer: a Western Cancer Study Group Trial

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Adjuvant therapy for resectable colorectal carcinoma with 5-fluorouracil portal vein infusion

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Postoperative adjuvant therapy

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report

1 reference

https://api.crossref.org/works/10.1002/14651858.CD005390.PUB2

7 January 2021

10.1002/14651858.CD005390.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

18646127

1 reference

Consolidated OpenCitations Corpus – April 2017